Aurinia Pharmaceuticals Inc.
AUPH Nasdaq
SEC CIK 1600620
Follow Aurinia Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$83.7M
+13.9% vs same quarter last year
Net income
$31.7M
+0.5% vs same quarter last year
EPS, diluted
$0.23
+0% vs same quarter last year
Operating cash flow
$46.4M
+4.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $283.1M | $287.2M |
| FY24 | $235.1M | $5.8M |
| FY23 | $175.5M | −$78M |
| FY22 | $134M | −$108.2M |
| FY21 | $45.6M | −$181M |
| FY20 | $50.1M | −$102.7M |
| FY19 | $318K | −$88.4M |
| FY18 | $463K | −$53.1M |
| FY17 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 88.5% | 37.1% | 101.5% |
| FY24 | 88% | −2% | 2.5% |
| FY23 | 91.9% | −52.2% | −44.4% |
| FY22 | 95.8% | −83.2% | −80.7% |
| FY21 | 97.6% | −396.3% | −396.9% |
| FY20 | 100% | −208.1% | −204.9% |
| FY19 | 100% | −28598.4% | −27794% |
| FY18 | - | −11930.9% | −11464.1% |
| FY17 | - | - | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $98.2M |
| FY24 | $40.2M |
| FY23 | $0 |
| FY22 | $0 |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | - |
| FY17 | - |
- Aurinia Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Aurinia Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | 101.5% | −30.6% |
| FY24 | 2.5% | −47% |
| FY23 | −44.4% | −58% |
| FY22 | −80.7% | −80.4% |
| FY21 | −396.9% | −71.9% |
| FY20 | −204.9% | −62.2% |
| FY19 | −27794% | −46.3% |
| FY18 | −11464.1% | −49.6% |
| FY17 | - | −45.9% |